Journal
MOVEMENT DISORDERS
Volume 25, Issue 11, Pages 1670-1674Publisher
WILEY-LISS
DOI: 10.1002/mds.23148
Keywords
PD; MitoQ; mitochondria; oxidative damage; neuroprotection
Categories
Funding
- Antipodean Pharmaceuticals Inc.
- MRC [MC_U105663142] Funding Source: UKRI
- Medical Research Council [MC_U105663142] Funding Source: researchfish
Ask authors/readers for more resources
Multiple lines of evidence point to mitochondrial oxidative stress as a potential pathogenic cause for Parkinson's disease (PD). MitoQ is a powerful mitochondrial antioxidant. It is absorbed orally and concentrates within mitochondria where it has been shown to protect against oxidative damage. We enrolled 128 newly diagnosed untreated patients with PD in a double-blind study of two doses of MitoQ compared with placebo to explore the hypothesis that, over 12 months, MitoQ would slow the progression of PD as measured by clinical scores, particularly the Unified Parkinson Disease Rating Scale. We showed no difference between MitoQ and placebo on any measure of PD progression. MitoQ does not slow the progression of PD, and this finding should be taken into account when considering the oxidative stress hypothesis for the pathogenesis of PD. (C) 2010 Movement Disorder Society
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available